Jens Y. Humrich

Jens Y. Humrich

Auto-generated profile, based on publicly available information

Jens Y. Humrich

A Department of Rheumatology , University Hospital Schleswig-Holstein , Lübeck , Germany

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JHJens Y. Humrich
Jens Y. Humrich
HMHenner Morbach
Henner Morbach
RUReinmar Undeutsch
Reinmar Undeutsch
PEPhilipp Enghard
Philipp Enghard
SRStefan Rosenberger
Stefan Rosenberger
GRGabriela Riemekasten
Gabriela Riemekasten
The origins and consequences of a regulatory T cell (Treg) disorder in systemic lupus erythematosus (SLE) are poorly understood. In the (NZBxNZW) F1mouse model of lupus, we found that CD4+Foxp3+Treg failed to maintain a competitive pool size in the peripheral lymphoid organs resulting in a progressive homeostatic imbalance of CD4+Foxp3+Treg and CD4+Foxp3−conventional T cells (Tcon). In addition, Treg acquired phenotypic changes that are reminiscent of IL-2 deficiency concomitantly to a progressive decline in IL-2-producing Tcon and an increase in activated, IFN-γ-producing effector Tcon. Nonetheless, Treg from lupus-prone mice were functionally intact and capable to influence the course of disease. Systemic reduction of IL-2 levels early in disease promoted Tcon hyperactivity, induced the imbalance of Treg and effector Tcon, and strongly accelerated disease progression. In contrast, administration of IL-2 partially restored the balance of Treg and effector Tcon by promoting the homeostatic proliferation of endogenous Treg and impeded the progression of established disease. Thus, an acquired and self-amplifying disruption of the Treg-IL-2 axis contributed essentially to Tcon hyperactivity and the development of murine lupus. The reversibility of this homeostatic Treg disorder provides promising approaches for the treatment of SLE.

3 April 2015 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
KKKatharina Kopetschke
Katharina Kopetschke
JKJan Klocke
Jan Klocke
AGAnna-Sophie Grießbach
Anna-Sophie Grießbach
JHJens Y Humrich
Jens Y Humrich
RBRobert Biesen
Robert Biesen
GRGabriela Riemekasten
Gabriela Riemekasten
Introduction: Urinary T cells represent a reliable noninvasive biomarker for proliferative Lupus nephritis (LN). Little is known about the presence of T cell subsets, B cells and macrophages in the urine although they may further improve the validity of urinary cellular biomarkers for LN. Methods: We analyzed contemporaneous blood and urine samples of patients with active LN (n = 19), other Systemic Lupus Erythematosus (SLE) patients (n = 79) and urine samples of patients with diabetic nephropathy (DN; n = 14) and anti-neutrophil cytoplasmatic antibody (ANCA) associated vasculitis (AAV; n = 11) by flow cytometry. Results: Numbers of urinary T cells, B cells and macrophages correlated with disease activity and were significantly higher in the active LN group. Urinary T cells showed excellent distinction of patients with active LN, CD8+ T cells (AUC of ROC = 1.000) and CD4+ T cells (AUC = 0.9969) alike. CD19+ B cells (AUC = 0.7823) and CD14+ macrophages (AUC = 0.9066), as well as the clinical standard proteinuria (AUC = 0.9201), failed to reach these high standards. Patients with DN or AAV also showed increased urinary cell counts, although the CD4/CD8-ratio was significantly lower in SLE compared to in DN (p = 0.0006). Urinary CD4+ T cells of active LN patients proved to be mainly of effector memory phenotype and expressed significantly more CD40L and ki67 than corresponding blood cells. Urinary Treg counts correlated with disease activity. Conclusions: Despite of detectable urinary cell counts for B cells and macrophages, T cells remain the best urinary cellular biomarker for LN. A low CD4/CD8-ratio seems to be characteristic for LN.

27 February 2013 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
OWOlivia Weigert
Olivia Weigert
CSCaroline von Spee
Caroline von Spee
RUReinmar Undeutsch
Reinmar Undeutsch
LKLutz Kloke
Lutz Kloke
JHJens Y Humrich
Jens Y Humrich
GRGabriela Riemekasten
Gabriela Riemekasten
Introduction: The ability to ameliorate murine lupus renders regulatory T cells (Treg) a promising tool for the treatment of systemic lupus erythematosus (SLE). In consideration to the clinical translation of a Treg-based immunotherapy of SLE, we explored the potential of CD4+Foxp3+ Treg to maintain disease remission after induction of remission with an established cyclophosphamide (CTX) regimen in lupus-prone (NZBxNZW) F1 mice. As a prerequisite for this combined therapy, we also investigated the impact of CTX on the biology of endogenous Treg and conventional CD4+ T cells (Tcon). Methods: Remission of disease was induced in diseased (NZBxNZW) F1 mice with an established CTX regimen consisting of a single dose of glucocorticosteroids followed by five day course with daily injections of CTX. Five days after the last CTX injection, differing amounts of purified CD4+Foxp3+CD25+ Treg were adoptively transferred and clinical parameters, autoantibody titers, the survival and changes in peripheral blood lymphocyte subsets were determined at different time points during the study. The influence of CTX on the numbers, frequencies and proliferation of endogenous Treg and Tcon was analyzed in lymphoid organs by flow cytometry. Results: Apart from abrogating the proliferation of Tcon, we found that treatment with CTX induced also a significant inhibition of Treg proliferation and a decline in Treg numbers in lymphoid organs. Additional adoptive transfer of 1.5 × 106 purified Treg after the CTX regimen significantly increased the survival and prolonged the interval of remission by approximately five weeks compared to mice that received only the CTX regimen. The additional clinical amelioration was associated with an increase in the Treg frequency in the peripheral blood indicating a compensation of CTX-induced Treg deficiency by the Treg transfer. Conclusions: Treg were capable to prolong the interval of remission induced by conventional cytostatic drugs. This study provides valuable information and a first proof-of-concept for the feasibility of a Treg-based immunotherapy in the maintenance of disease remission in SLE.

23 June 2016 in Expert Review of Clinical Immunology
Verified
Journal Article
Closed access
JHJens Y. Humrich
Jens Y. Humrich
GRGabriela Riemekasten
Gabriela Riemekasten
The pathogenesis of systemic lupus erythematosus (SLE) involves an acquired deficiency of the cytokine IL-2, an essential growth and survival factor for regulatory T cells (Treg), which play an important role in the control of autoimmunity in SLE. In contrast to currently available therapies that broadly suppress the immune system, low-dose IL-2 therapy in SLE aims to compensate the pre-existing IL-2 deficiency and thus to restore a physiological state, where Treg can regain their ability to efficiently counteract autoimmunity. Areas covered: Here we summarize key findings that led to the development of this novel therapeutic concept and will highlight the key rationales for the clinical translation of low-dose IL-2 therapy in SLE. Expert commentary: The concept of low-dose IL-2 therapy in SLE has evolved from pathophysiological findings and thus can be considered a selective biological treatment strategy in SLE. Preliminary results from phase I/II studies are promising by proving selective Treg expansion and by providing first evidence for the clinical efficacy of low-dose IL-2 therapy in SLE.

9 December 2005 in Immunology
Verified
Journal Article
Closed access
PDF file
JHJens Y. Humrich
Jens Y. Humrich
JHJan H. Humrich
Jan H. Humrich
MAMarco Averbeck
Marco Averbeck
PTPeter Thumann
Peter Thumann
CTChristian Termeer
Christian Termeer
LJLars Jenne
Lars Jenne

28 March 2007 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
JHJens Y. Humrich
Jens Y. Humrich
PTPeter Thumann
Peter Thumann
SGSebastian Greiner
Sebastian Greiner
JHJan H. Humrich
Jan H. Humrich
MAMarco Averbeck
Marco Averbeck
LJLars Jenne
Lars Jenne